Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data shows
Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data shows Nov 18 (Reuters) - Bristol Myers Squibb BMY.N said on Wednesday that preliminary data from two late-stage studies showed its experimental treatment for psychosis associated with Alzheimer's disease improved patient symptoms.
Investors are closely watching whether Cobenfy, currently approved in the United States to treat schizophrenia, can be expanded into Alzheimer's treatment and drive future growth for the company.
Here are more details:
In both studies, Cobenfy — chemically known as KarXT — was associated with improvements in clinician-observed scores of hallucinations and delusions and overall disease severity, Bristol said
Alzheimer's is a devastating neurodegenerative disease and the most common type of dementia in adults. The company estimates about 30-50% of Alzheimer's patients experience symptoms such as hallucinations and delusions
The preliminary results are the first to be disclosed from the ongoing late-stage program
In a 12-week study, patients treated with the drug showed an average reduction in symptoms such as hallucination and delusion by 12 points from 14.4 at the start of the study
Among patients who completed treatment for 52 weeks, the drug was generally well tolerated, with low rates of discontinuation, the drugmaker said
At 52 weeks, treatment-related side effects occurred in 65.1% of patients, serious treatment-related side effects occurred in 7.7%, while 4.7% discontinued treatment due to side effects
(Reporting by Sneha S K; Editing by Diti Pujara)
((Sneha.SK@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb
See all newsEvotec rises after second FDA IND acceptance in Bristol Myers Squibb partnership
AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco
Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data shows
Brief: Bristol Myers Squibb Presents First Clinical Data From Two Phase 3 Studies In The Adept Program Evaluating Karxt For Psychosis Associated With Alzheimer’S Disease
Brief: Sichuan Biokin Pharmaceutical's Unit Receives Milestone Payment From Bristol-Myers Squibb